5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance
2009 ◽
Vol 7
(2)
◽
pp. 285
◽
2007 ◽
Vol 5
(4)
◽
pp. 221-222
Keyword(s):
2004 ◽
Vol 2
(3)
◽
pp. 125-126
◽
Keyword(s):
2013 ◽
Keyword(s):
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 1139-1139
Keyword(s):